ArticleScientific reports2018
Effect of tyrosine kinase inhibitors on renal handling of creatinine by MATE1.
Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 69 citations in OpenAlex.
- Efficacy and safety of tepotinib in Asian patients with advanced NSCLC with MET exon 14 skipping enrolled in VISION.British journal of cancer · 2024Trial
- Long-term experience with tepotinib in Japanese patients with MET exon 14 skipping NSCLC from the Phase II VISION study.Cancer science · 2024Trial
- Clinical and metabolomic characterization of Brivanib-Induced hypertension in metastatic colorectal cancer.Cancer medicine · 2023Trial
- Incidence and Magnitude of Pseudo-decrease in Kidney Function With Oral Epidermal Growth Factor Inhibitor Osimertinib.Kidney medicine · 2026Article
- Role of solute carrier transporters in the biodistribution and toxicity of chemotherapeutic drugs.Pharmacological reviews · 2026Review
- Pseudo-Acute Kidney Injury With Tyrosine Kinase Inhibitors: Utility of the Creatinine-to-Cystatin C Ratio.Kidney international reports · 2026Article
- Molecularly Targeted Cancer Medications and Kidney Health.JAMA network open · 2025Article
- Safety, pharmacokinetic, pharmacodynamic, and efficacy properties of orally administered APG-2449 in patients with advancedEClinicalMedicine · 2025Article
- Predicting OCT2/MATEs-Mediated Drug Interactions in Healthy Volunteers and Patients with Chronic Kidney Disease: Insights from Extended Clearance Concept, Endogenous Biomarkers, and In Vitro Inhibition Studies (Perspectives from the International Transporter Consortium).Clinical pharmacology and therapeutics · 2025Review
- Ten tips for an onco-nephrology clinic.Clinical kidney journal · 2025Review
- Variable power functional dilution adjustment of spot urine.Scientific reports · 2025Article
- An Integrated Approach for Representing Knowledge on the Potential of Drugs to Cause Acute Kidney Injury.Drug safety · 2025Article
- Practical considerations in the management of patients treated with bosutinib for chronic myeloid leukemia.Annals of hematology · 2024Review
- The incidence and trends of proteinuria, azotemia and hypertension in cats receiving toceranib phosphate.Journal of feline medicine and surgery · 2024Article
- Brief Report: Tyrosine Kinase Inhibitors for Lung Cancers That Inhibit MATE-1 Can Lead to "False" Decreases in Renal Function.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2024Article
- Pseudo-AKI associated with targeted anti-cancer agents-the truth is in the eye of the filtration marker.Clinical kidney journal · 2023Article
- Time to Rethink the Current Paradigm for Assessing Kidney Function in Drug Development and Beyond.Clinical pharmacology and therapeutics · 2022Review
- Role of Drug Transporters in Elucidating Inter-Individual Variability in Pediatric Chemotherapy-Related Toxicities and Response.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Safety of Tepotinib in Patients With MET Exon 14 Skipping NSCLC and Recommendations for Management.Clinical lung cancer · 2022Article
- TRK inhibitor activity and resistance in TRK fusion-positive cancers in adults.Cancer genetics · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Creatinine is actively secreted across tubular epithelial cells via organic cation transporter 2 (OCT2) and multidrug and toxin extrusion 1 (MATE1). We previously showed that the tyrosine kinase inhibitor (TKI) crizotinib inhibits OCT2-mediated transport of creatinine. In the present work, we examined the inhibitory potency of TKIs, including crizotinib, on MATE1-mediated transport of creatinine. Then, we used the kinetic parameters estimated in this and the previous work to predict the potential impact of TKIs on serum creatinine level (SCr) via reversible inhibition of creatinine transport. Crizotinib inhibited [
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.